Endowments provide a lasting financial donation that greatly impacts cancer research, education, and quality of care long after the initial gift is made.
The Mission Endowment – Building a Future
The Conquer Cancer Foundation established its Mission Endowment to provide a long-term base of support to advance our critical mission to improve the care and treatment of people living with cancer. The Endowment is the cornerstone of the Foundation’s efforts to extend the reach and impact of our work, and will allow us to continue to support the very best opportunities for scientific research and professional development, and patient education well into the future. Commitment to the Mission Endowment provides the opportunity to support key mission activities of the Foundation and ASCO and provides a stable flow of funds to increase grant funding, sustain existing programs, develop new initiatives, reach new audiences, and Work Together To Create a World Free From the Fear of Cancer.
Endowment Programs Supporting Cancer Research
Support for research is critical to achieve key milestones in the fight against cancer. The Conquer Cancer Foundation is proud to have supported many of these advances through its Grants and Awards Program. From our first research grant in 1984, more than $89 million has been awarded in research grants to launch cancer research careers, advance discovery, and conquer cancer. The impact has been global, with more than a thousand clinical and translational scientists at all levels of their career and from diverse cancer research areas hailing from over 60 countries worldwide.
The Foundation has been able to establish several endowments in order to expand our research endeavors. These endowments are supported by donors that play a vital role in our success and we can now allow the funds to live on forever and continue to generate income for the important programs that are supported by the Foundation. Below is a list of the current endowments at the Conquer Cancer Foundation.
Evelyn H. Lauder Young Investigator Award Endowment Fund
|The fund was established in 2012 to support the Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) in Memory of Evelyn H. Lauder. The endowment enables the Conquer Cancer Foundation to fund one YIA each year, starting in 2013, to enable young investigators to conduct pivotal breast cancer research. The YIA funds physicians who are within the last two years of their final subspecialty training at an academic institution, to aid their transition from a fellowship program to a faculty appointment. The fund was made possible by the enduring support of The Breast Cancer Research Foundation®, which was founded by Evelyn Lauder in 1993.|
John R. Durant, MD Young Investigator Award Endowment Fund
|The fund was established in 2013 to support the Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) in Memory of John R. Durant, MD. Dr. Durant was ASCO President from 1985-1986 and in 1995, became ASCO’s first Executive Vice-President. The endowment enables the Conquer Cancer Foundation to fund one YIA each year in all areas of cancer research. The YIA funds physicians who are within the last two years of their final subspecialty training at an academic institution, to aid their transition from a fellowship program to a faculty appointment. The fund was made possible by the generous support of Celgene Corporation.|
Gianni Bonadonna Breast Cancer Award and Lecture, Breast Cancer Research Fellowship
|The fund was established in 2007 to honor the achievements of Gianni Bonadonna, MD. Dr. Bonadonna is a pioneer in the field of cancer research whose ground-breaking research in adjuvant treatment of breast cancer and Hodgkin’s Disease has opened new avenues for increased survival of cancer patients. The endowment enables ASCO and the Conquer Cancer Foundation to award the Gianni Bonadonna Breast Cancer Award and Lecture and an accompanying Gianni Bonadonna Breast Cancer Research Fellowship grant. The fund is supported by a grant from GlaxoSmithKline Oncology.|
James B. Nachman Pediatric Oncology Fund
|The fund was established in 2012 to support the James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology, an award given in memory of James B. Nachman, MD, an internationally known cancer expert on pediatric cancers. Each year, a $3,000 award is presented to a junior faculty member who submits the highest-ranked abstract in pediatric oncology for presentation at the ASCO Annual Meeting.|
The Sally Gordon Young Investigator Award Endowment Fund
|The fund was established in 2013 to support the Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) in Memory of Sally Gordon. The endowment enables the Conquer Cancer Foundation to fund one YIA each year in all areas of cancer research. The YIA funds physicians who are within the last two years of their final subspecialty training at an academic institution, to aid their transition from a fellowship program to a faculty appointment.|
Endowment funds also provide an opportunity to honor the legacy of individuals who have had significant contributions to ASCO, the field of oncology, the oncology community, and patients around the world. The Foundation is seeking support to honor the legacy of these individuals:
Honoring the legacy of Dr. Jane Cooke Wright
Dr. Jane C. Wright was one of seven founding members of ASCO (the only woman among the founders) and the Society’s first Secretary/Treasurer, as well as a chemotherapy pioneer and renowned researcher. At a time when chemotherapy treatment was largely thought of as experimental, Dr. Wright pioneered the use of anticancer agents and developed new techniques for administering cancer chemotherapy. At one point in her career, Dr. Wright was the highest ranked African-American woman at a nationally recognized medical institution. She was not only a pioneer in the field of cancer research and treatment, but also a leader. Read More
Honoring the legacy of Dr. Emil Frei III
|Dr. Emil “Tom” Frei III was one of the world’s foremost oncologists and a leading researcher in cancer treatment whose work led to some of the first cures for a variety of pediatric and adult cancers. He was known as the “father of combination chemotherapy” due to his collaborative work which demonstrated that multiple chemotherapy agents could produce lasting remissions in children with acute lymphocytic leukemia (ALL). At the time, this disease was uniformly fatal, and single chemotherapy drugs could only bring it into temporary remission. Today, childhood leukemia has a long-term survival rate of more than 80 percent. Read More|
Honoring the legacy of Dr. Jane C. Weeks, MD, MSC, FASCO
|Dr. Jane C. Weeks was widely regarded as a visionary and pioneer in the field of health services and comparative effectiveness research. Believing she could make a difference in research on the benefits, risks and results of cancer treatment, Dr. Weeks gave up clinical practice early in her career to establish and direct the Center for Outcomes and Policy Research at Dana-Farber Cancer Institute. She was an early recipient of the Conquer Cancer Foundation of ASCO Career Development Award (CDA) and later mentored multiple young investigators who successfully received Conquer Cancer Foundation research grants. In recognition of her broad commitment to exceptional mentoring, Dr. Weeks received the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School. Read More|
If you would like to learn more, please call us at 571-483-1700 or email us at email@example.com to discuss your philanthropic goals.